4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

Published on 20 Jan 2022 on Zacks via Yahoo Finance

4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

Despite the success of COVID-19 vaccines and medicines, the biotech sector underperformed the broader market in 2021. However, the sector is expected to pick up in 2022 due to its strong fundamentals.

In this defensive sector, Vertex Pharmaceuticals Incorporated VRTX is a good stock to own.

There are several reasons to own the stock.

Read the rest of the article

NASDAQ.KYMR price evolution

NASDAQ.BNTX price evolution

NASDAQ.CRSP price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc (NASDAQ:KYMR) CFO Bruce Jacobs has sold 3,934 shares of the company's sto...

GuruFocus.com via Yahoo Finance 4 Mar 2024

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming...

Investors in Kymera Therapeutics, Inc. (NASDAQ:KYMR) had a good week, as its shares rose 8.3% to ...

Simply Wall St. via Yahoo Finance 24 Feb 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript February 22, 2024 Kymera...

Insider Monkey via Yahoo Finance 23 Feb 2024

Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results

Collaboration Revenues: Increased to $47.9 million in Q4 and $78.6 million for the full year 2023...

GuruFocus.com via Yahoo Finance 22 Feb 2024

Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR)

On February 21, 2024, Director Jeffrey Albers sold 5,000 shares of Kymera Therapeutics Inc (NASDA...

GuruFocus.com via Yahoo Finance 21 Feb 2024

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?

Wall Street expects a year-over-year increase in earnings on higher revenues when Kymera Therapeu...

Zacks via Yahoo Finance 15 Feb 2024

Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc

Jared Gollob, Chief Medical Officer of Kymera Therapeutics Inc (NASDAQ:KYMR), sold 46,137 shares ...

GuruFocus.com via Yahoo Finance 10 Feb 2024

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 34% Share Price Surge Not Quite Adding Up

The Kymera Therapeutics, Inc. (NASDAQ:KYMR) share price has done very well over the last month, p...

Simply Wall St. via Yahoo Finance 18 Dec 2023

BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc

On November 3, 2023, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio), a prominent investment fir...

GuruFocus.com via Yahoo Finance 7 Nov 2023

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript November 4, 2023 Operato...

Insider Monkey via Yahoo Finance 5 Nov 2023

News

4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022

NASDAQ.KYMR price evolution

NASDAQ.BNTX price evolution

NASDAQ.CRSP price evolution

Want to become a better investor?